Drug Trial Radar · NCT03281954
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
Last checked: Nov 20, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,550
Actual
Start
Dec 19, 2017
Primary completion
Dec 31, 2024
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- NSABP Foundation IncResearch network
- Sponsor type
- Research network
- Collaborators
- Genentech, Inc.; Hoffmann-La Roche
- First posted
- Sep 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a drug that looks like the study drug but contains no medication.) The usual chemotherapy in this study is paclitaxel (WP) and carboplatin followed by doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple negative breast cancer, no additional treatment is given unless the cancer returns. This study will also look at continuing treatment after surgery with atezolizumab or the placebo. To be better, atezolizumab given with the neoadjuvant therapy should be better at: 1) decreasing the amount of tumor in the breast than the placebo given with the usual chemotherapy and 2) decreasing the chance of the cancer from returning after surgery. Another purpose of this study is to test the good and bad effects of atezolizumab when added to the usual chemotherapy. Atezolizumab may keep your cancer from growing but it can also cause side effects.
Conditions
- Triple Negative Breast Cancer
Interventions
PlaceboDrug
Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses. Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles. \+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used. Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose.
AtezolizumabDrug
Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses. Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles. \+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used. Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS)Time frame: From randomization until event, through study follow up to the time target number of events is obtained, up to 5 years
Locations
217 sites in 2 countries. Site status is shown where the registry gives one.
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Katmai Oncology Group
Anchorage, Alaska
St. Bernard's Medical Center
Jonesboro, Arkansas
St. Bernard's Medical Center
Paragould, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Arrowhead Regional Medical Center
Colton, California
City of Hope
Duarte, California
Kaiser Permanente-Fontana
Fontana, California
Kaiser Permanente-Harbor City
Harbor City, California
Kaiser Permanente-Irvine
Irvine, California
Cancer and Blood Specialty Clinic
Los Alamitos, California
Kaiser Permanente-Sunset
Los Angeles, California
Kaiser Permanente-West Los Angeles
Los Angeles, California
Kaiser Permanente-Panorama City
Panorama City, California
Kaiser Permanente-Riverside
Riverside, California
Kaiser Permanente Medical Group
San Diego, California
Kaiser Permanente-Zion
San Diego, California
Kaiser Permanente - Otay
San Diego, California
Kaiser Permanente- San Marcos
San Marcos, California
City of Hope - South Pasadena
South Pasadena, California
Torrance Memorial Physician Network
Torrance, California
City of Hope - Upland
Upland, California
PIH Health
Whittier, California
Kaiser Permanente-Woodland Hills
Woodland Hills, California
Mount Sinai Comprehensive Cancer Center Aventura
Aventura, Florida
Memorial Healthcare System Office of Human Research
Hollywood, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
UF Health Cancer Center at Orlando Health
Orlando, Florida
Gwinnett Hospital System Center for Cancer Care
Duluth, Georgia
Gwinnett Hospital System Center for Cancer Care
Lawrenceville, Georgia
Gwinnett Hospital System Center for Cancer Care
Snellville, Georgia
Illinois Cancer Care-Bloomington
Bloomington, Illinois
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Affiliated Oncologists
Chicago Ridge, Illinois
Cancer Care Specialists of Central Illinois
Decatur, Illinois
Decatur Memorial Hospital
Decatur, Illinois
Crossroads Cancer Center
Effingham, Illinois
Showing 40 of 217 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.